Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document

Alberto Lapini; Orazio Caffo; Giovanni Pappagallo; Roberto Iacovelli; Rolando Maria D'Angelillo; Vittorio Vavassori; Roberta Ceccarelli; Sergio Bracarda; Barbara Alicja Jereczek-Fossa; Luigi Da Pozzo; Giario Natale Conti

doi:10.3390/cancers11121908

Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document

Alberto Lapini, Orazio Caffo, Giovanni Pappagallo, Roberto Iacovelli, Rolando Maria D'Angelillo, Vittorio Vavassori, Roberta Ceccarelli, Sergio Bracarda, Barbara Alicja Jereczek-Fossa, Luigi Da Pozzo, Giario Natale Conti

IRCCS Fondazione Policlinico Universitario A. Gemelli

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The availability of a number of agents that are efficacious in patients with metastatic prostate cancer (mPC) has led to them being used sequentially, and this has prolonged patient survival. However, in order to maximize their efficacy, clinicians need to be able to obtain a reliable picture of disease evolution by means of monitoring procedures.

METHODS: As the intensive monitoring protocols used in pivotal trials cannot be adopted in everyday clinical practice and there is no agreement among the available guidelines, a multidisciplinary panel of Italian experts met to develop recommendations for monitoring mPC patients using a modified Delphi method.

RESULTS: The consensus project considered methods of clinically, radiographically, and biochemically monitoring patients with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer undergoing chemotherapy and/or hormonal treatment. The panelists also considered the methods and timing of monitoring castration levels, bone health, and the metabolic syndrome during androgen deprivation therapy.

CONCLUSIONS: The recommendations, which were drawn up by experts following a formal and validated consensus procedure, will help clinicians face the everyday challenges of monitoring metastatic prostate cancer patients.

Original language	English
Journal	Cancers
Volume	11
Issue number	12
DOIs	https://doi.org/10.3390/cancers11121908
Publication status	Published - Dec 1 2019

Access to Document

10.3390/cancers11121908

Cite this

Lapini, A., Caffo, O., Pappagallo, G., Iacovelli, R., D'Angelillo, R. M., Vavassori, V., Ceccarelli, R., Bracarda, S., Jereczek-Fossa, B. A., Da Pozzo, L., & Conti, G. N. (2019). Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. Cancers, 11(12). https://doi.org/10.3390/cancers11121908

Lapini, A, Caffo, O, Pappagallo, G, Iacovelli, R, D'Angelillo, RM, Vavassori, V, Ceccarelli, R, Bracarda, S, Jereczek-Fossa, BA, Da Pozzo, L & Conti, GN 2019, 'Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document', Cancers, vol. 11, no. 12. https://doi.org/10.3390/cancers11121908

@article{6a5fa8fdac394cbc9e70135f23fed5f3,

title = "Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document",

abstract = "BACKGROUND: The availability of a number of agents that are efficacious in patients with metastatic prostate cancer (mPC) has led to them being used sequentially, and this has prolonged patient survival. However, in order to maximize their efficacy, clinicians need to be able to obtain a reliable picture of disease evolution by means of monitoring procedures.METHODS: As the intensive monitoring protocols used in pivotal trials cannot be adopted in everyday clinical practice and there is no agreement among the available guidelines, a multidisciplinary panel of Italian experts met to develop recommendations for monitoring mPC patients using a modified Delphi method.RESULTS: The consensus project considered methods of clinically, radiographically, and biochemically monitoring patients with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer undergoing chemotherapy and/or hormonal treatment. The panelists also considered the methods and timing of monitoring castration levels, bone health, and the metabolic syndrome during androgen deprivation therapy.CONCLUSIONS: The recommendations, which were drawn up by experts following a formal and validated consensus procedure, will help clinicians face the everyday challenges of monitoring metastatic prostate cancer patients.",

author = "Alberto Lapini and Orazio Caffo and Giovanni Pappagallo and Roberto Iacovelli and D'Angelillo, {Rolando Maria} and Vittorio Vavassori and Roberta Ceccarelli and Sergio Bracarda and Jereczek-Fossa, {Barbara Alicja} and {Da Pozzo}, Luigi and Conti, {Giario Natale}",

year = "2019",

month = dec,

day = "1",

doi = "10.3390/cancers11121908",

language = "English",

volume = "11",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI AG",

number = "12",

}

TY - JOUR

T1 - Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer

T2 - A Multidisciplinary Consensus Document

AU - Lapini, Alberto

AU - Caffo, Orazio

AU - Pappagallo, Giovanni

AU - Iacovelli, Roberto

AU - D'Angelillo, Rolando Maria

AU - Vavassori, Vittorio

AU - Ceccarelli, Roberta

AU - Bracarda, Sergio

AU - Jereczek-Fossa, Barbara Alicja

AU - Da Pozzo, Luigi

AU - Conti, Giario Natale

PY - 2019/12/1

Y1 - 2019/12/1

N2 - BACKGROUND: The availability of a number of agents that are efficacious in patients with metastatic prostate cancer (mPC) has led to them being used sequentially, and this has prolonged patient survival. However, in order to maximize their efficacy, clinicians need to be able to obtain a reliable picture of disease evolution by means of monitoring procedures.METHODS: As the intensive monitoring protocols used in pivotal trials cannot be adopted in everyday clinical practice and there is no agreement among the available guidelines, a multidisciplinary panel of Italian experts met to develop recommendations for monitoring mPC patients using a modified Delphi method.RESULTS: The consensus project considered methods of clinically, radiographically, and biochemically monitoring patients with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer undergoing chemotherapy and/or hormonal treatment. The panelists also considered the methods and timing of monitoring castration levels, bone health, and the metabolic syndrome during androgen deprivation therapy.CONCLUSIONS: The recommendations, which were drawn up by experts following a formal and validated consensus procedure, will help clinicians face the everyday challenges of monitoring metastatic prostate cancer patients.

AB - BACKGROUND: The availability of a number of agents that are efficacious in patients with metastatic prostate cancer (mPC) has led to them being used sequentially, and this has prolonged patient survival. However, in order to maximize their efficacy, clinicians need to be able to obtain a reliable picture of disease evolution by means of monitoring procedures.METHODS: As the intensive monitoring protocols used in pivotal trials cannot be adopted in everyday clinical practice and there is no agreement among the available guidelines, a multidisciplinary panel of Italian experts met to develop recommendations for monitoring mPC patients using a modified Delphi method.RESULTS: The consensus project considered methods of clinically, radiographically, and biochemically monitoring patients with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer undergoing chemotherapy and/or hormonal treatment. The panelists also considered the methods and timing of monitoring castration levels, bone health, and the metabolic syndrome during androgen deprivation therapy.CONCLUSIONS: The recommendations, which were drawn up by experts following a formal and validated consensus procedure, will help clinicians face the everyday challenges of monitoring metastatic prostate cancer patients.

U2 - 10.3390/cancers11121908

DO - 10.3390/cancers11121908

M3 - Article

C2 - 31805687

SN - 2072-6694

VL - 11

JO - Cancers

JF - Cancers

IS - 12

ER -

Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document

Abstract

Access to Document

Fingerprint

Cite this